BUZZ-Allurion Technologies rises on initial data from weight-loss device treatment

Reuters

Mar 21, 2025

** Shares of healthcare company Allurion Technologies > rise 25% to $2.85 in aftermarket trade

** Company says initial data shows patients treated with its device along with low doses of Novo Nordisk's NOVOb.CO semaglutide resulted in average total body weight loss of 20.3% and lean body mass increase to 68.5%

** Company's device called Allurion Balloon occupies space in the stomach and is designed to promote satiety and reduce food consumption

** The balloon is non-surgical, swallowed and is designed to naturally empty and be eliminated about 4 months later - ALUR

** Company says all 52 patients remained adherent to the GLP-1 medication through eight months

** Additional data on the combination approach is being collected and is expected to be presented at upcoming medical meetings - company

** Stock had fallen 88.5% in 2024

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2521249130"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2521249130\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2521249130?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-21 04:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521249130","market":"us","top_or_hot":-1,"title":"BUZZ-Allurion Technologies rises on initial data from weight-loss device treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Allurion Technologies rises on initial data from weight-loss device treatment </title></head><body><p>** Shares of healthcare company Allurion Technologies <alur.n>&gt; rise 25% to $2.85 in aftermarke<span>t trade</span> </alur.n></p><p>** Company says initial data shows patients treated with its device along with low doses of Novo Nordisk's <span>NOVOb.CO</span> semaglutide resulted in average total body weight loss of 20.3% and <span>lean body mass increase to 68.5%</span></p><p>** Company's device called Allurion Balloon occupies space in the stomach and is designed to promote satiety and reduce food consumption</p><p>     ** The balloon is non-surgical, swallowed and is designed to naturally empty and be eliminated about 4 months later - ALUR </p><p>** Company says all 52 patients remained adherent to the GLP-1 medication through eight months</p><p>** Additional data on the combination approach is being collected and is expected to be presented at upcoming medical meetings - company</p><p>** Stock had fallen 88.5% in 2024 </p><p> (Reporting by Sneha S K)</p><p> ((Sneha.SK@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Allurion Technologies rises on initial data from weight-loss device treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Allurion Technologies rises on initial data from weight-loss device treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-21 04:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Allurion Technologies rises on initial data from weight-loss device treatment </title></head><body><p>** Shares of healthcare company Allurion Technologies <alur.n>&gt; rise 25% to $2.85 in aftermarke<span>t trade</span> </alur.n></p><p>** Company says initial data shows patients treated with its device along with low doses of Novo Nordisk's <span>NOVOb.CO</span> semaglutide resulted in average total body weight loss of 20.3% and <span>lean body mass increase to 68.5%</span></p><p>** Company's device called Allurion Balloon occupies space in the stomach and is designed to promote satiety and reduce food consumption</p><p>     ** The balloon is non-surgical, swallowed and is designed to naturally empty and be eliminated about 4 months later - ALUR </p><p>** Company says all 52 patients remained adherent to the GLP-1 medication through eight months</p><p>** Additional data on the combination approach is being collected and is expected to be presented at upcoming medical meetings - company</p><p>** Stock had fallen 88.5% in 2024 </p><p> (Reporting by Sneha S K)</p><p> ((Sneha.SK@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALUR","symbol_name":"ALLURION TECHNOLOGIES","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL4N3Q31L4:1","article_id":"2521249130","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521249130","pubTimestamp":1742503315,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Allurion Technologies rises on initial data from weight-loss device treatment ** Shares of healthcare company Allurion Technologies > rise 25% to $2.85 in aftermarket trade ** Company says initial data shows patients treated with its device along with low doses of Novo Nordisk's NOVOb.CO semaglutide resulted in average total body weight loss of 20.3% and lean body mass increase to 68.5%** Company's device called Allurion Balloon occupies space in the stomach and is designed to promote satiety and reduce food consumption     ** The balloon is non-surgical, swallowed and is designed to naturally empty and be eliminated about 4 months later - ALUR ** Company says all 52 patients remained adherent to the GLP-1 medication through eight months** Additional data on the combination approach is being collected and is expected to be presented at upcoming medical meetings - company** Stock had fallen 88.5% in 2024   ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALUR":"ALLURION TECHNOLOGIES","BK4192":"特殊消费者服务"},"translate_title":"BUZZ-Allurion Technologies因减肥设备治疗的初步数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALUR":0.9},"content_text":"BUZZ-Allurion Technologies rises on initial data from weight-loss device treatment ** Shares of healthcare company Allurion Technologies > rise 25% to $2.85 in aftermarket trade ** Company says initial data shows patients treated with its device along with low doses of Novo Nordisk's NOVOb.CO semaglutide resulted in average total body weight loss of 20.3% and lean body mass increase to 68.5%** Company's device called Allurion Balloon occupies space in the stomach and is designed to promote satiety and reduce food consumption     ** The balloon is non-surgical, swallowed and is designed to naturally empty and be eliminated about 4 months later - ALUR ** Company says all 52 patients remained adherent to the GLP-1 medication through eight months** Additional data on the combination approach is being collected and is expected to be presented at upcoming medical meetings - company** Stock had fallen 88.5% in 2024  (Reporting by Sneha S K) ((Sneha.SK@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}